Introduction
Chronic myeloid leukaemia (CML) is a malignant myeloproliferative disorder characterised at the cytogenetic level by a reciprocal translocation between chromosomes 9 and 22. This results in the juxtaposition and fusion of parts of the BCR and ABL genes on the Philadelphia (Ph) chromosome and the production of a protein tyrosine kinase (p210 bcr/abl ) that is presumed to be responsible for the biological and clinical features of the disease. 1, 2 Interferon (IFN)-␣ has been used to treat CML patients with beneficial results in terms of haematological response and re-emergence of Ph chromosome-negative haemopoiesis. 3, 4 Moreover, there is a significant survival advantage compared with alternative forms of chemotherapy. [5] [6] [7] Response to IFN-␣ is gradual, typically taking months to become evident, which suggests that the mode of action of IFN-␣ may be subtle.
GM, but not normal bone marrow (NBM) CFU-GM, to produce secondary CFU-GM upon replating is significantly reduced in the presence of pharmacological levels of IFN-␣. 11 This finding provided the first evidence for a selective inhibitory effect of IFN-␣ on CML progenitor cell kinetics. More recently, we have found that the tyrosine kinase inhibitor, STI571, also preferentially suppresses the replating ability of CML CFU-GM. 12 Since the CFU-GM compartment is the fastest expanding component of the myeloid series in untreated CML, 2, 13, 14 these findings suggest that at least part of the mode of action of IFN-␣ and STI571 is to selectively reduce the expansion of the leukaemic clone at the myeloid progenitor cell level.
The relatively slow response of CML patients to IFN-␣ therapy and its toxicity have led to a search for additional agents which could be combined with IFN-␣ to increase therapeutic efficacy. In this regard, the two agents which have been evaluated in vitro are cytosine arabinoside (Ara-C) and all-trans retinoic acid (ATRA). Ara-C is an S-phase-specific cytotoxic agent which has a selective effect against CML progenitors in vitro. 15, 16 Ara-C has been administered with IFN-␣ to treat CML patients and significant improvements in both survival and cytogenetic responses have been reported, compared with the use of IFN-␣ alone. 17 In some studies, 18 but not others, 19 ATRA also has been found to have different effects on normal and CML progenitor cells in culture. Evidence of extensive 'cross-talk' between the intracellular signalling pathways activated by IFN-␣ and ATRA 20 identifies ATRA as a potential candidate for combined therapy with IFN-␣.
Here we report the in vitro effects of Ara-C and ATRA alone and in combination with IFN-␣ on CML progenitor cells in vitro. The results suggest that IFN-␣ and Ara-C/ATRA would be most effective if used as alternate rather than concomitant therapies since they appear to act by different mechanisms and Ara-C/ATRA may counteract the therapeutic advantage of IFN-␣ in CML.
Methods

Patients and samples
All samples were obtained with informed consent and local research ethics committee approval. Peripheral blood samples were obtained from patients in chronic phase CML during routine outpatient visits to the Hammersmith Hospital. Samples were considered eligible for use if the patient was either untreated on presentation or had received no treatment other than hydroxyurea for at least 3 months. Contemporaneous cytogenetic data were available in 10/15 cases studied. All 10 were 100% Ph chromosome-positive. Normal bone marrow was obtained from donations for allogeneic transplantation.
CFU-GM assay
Mononuclear cells (MNC) were obtained by density gradient centrifugation over Lymphoprep (Nycomed, Oslo, Norway) and depleted of adherent cells by a 2-h incubation in alpha medium (Gibco, Paisley, UK) plus 15% fetal calf serum in tissue culture plastic flasks at 37°C in 5% CO 2 in air. Nonadherent MNC were plated at 1 × 10 5 /ml in methylcellulose containing serum (methocult H4230, Metachem Diagnostics, Northampton, UK) and supplemented with recombinant human cytokines (100 ng/ml G-CSF (Granocyte, Chugai Pharma, London UK), 1 ng/ml GM-CSF, 5 ng/ml IL-3 and 20 ng/ml SCF (First Link, West Midlands, UK)) in Petri dishes. The cultures were incubated for 7 days at 37°C in humidified 5% CO 2 in air for 7 days and then colonies consisting of at least 50 cells were scored on an inverted microscope.
In some experiments colonies were grown in the presence of 0 or 100 U/ml IFN-␣ (Roche Products, Welwyn Garden City, UK), 0, 0.5, 5, 50 or 500 ng/ml Ara-C (Sigma, Poole, UK) or 0, 0.015, 0.15, 1.5 or 15 ng/ml ATRA (Sigma). Additional experiments also included CFU-GM grown in the presence of both IFN-␣ and selected concentrations of either Ara-C or ATRA with appropriate controls. Stocks of IFN-␣ and Ara-C were dissolved in alpha medium and stored in aliquots at −70°C. ATRA was dissolved in DMSO (BDH, Poole, UK) before aliquotting and storing at −70°C in the dark. The final concentration of DMSO was adjusted to 0.06% in all ATRA cultures, including controls.
CFU-GM replating assay Secondary colony formation:
For each experimental group investigated, 120 consecutive colonies consisting of 50 or more cells after 7 days of culture were plucked from the methylcellulose using a sterile Eppendorf pipette. Each colony was vigorously dispersed in a separate well of a 96-well microtitre plate containing 100 l of methylcellulose plus serum and cytokines as previously detailed. 11 The plates were incubated for a further 7 days at 37°C in humidified 5% CO 2
Figure 1
The effects of Ara-C on the plating efficiency of normal (NBM) or CML CFU-GM. The dose-response experiments were performed to determine the highest concentration of Ara-C (ie 0.5 ng/ml) which was not significantly toxic to either NBM or CML CFU-GM. Results are the means ± s.e.m. of six (NBM) or 11 (CML) experiments, respectively. Normal bone marrow controls yielded 379 ± 60 CFU-GM/10 5 mononuclear cells and CML controls yielded 648 ± 243. Statistical analysis was performed by Wilcoxon's signed rank test.
Leukemia in air. Each well was scored for the presence and number of secondary colonies of more than 50 cells.
Data analysis:
The data were analysed using a Microsoft Excel spreadsheet, version 5.0 (Microsoft Corporation, Redmond, WA, USA) or a computer programme customwritten by Dr NM Blackett (Department of Haematology, ICSM). The raw data are the number (n) of secondary CFU-GM produced by each individual primary replated colony. A cumulative distribution of the proportion of primary CFU-GM producing more than n secondary CFU-GM is plotted on a logarithmic y axis. The x axis is expressed as log 2 n which reflects the number of cell doublings required to produce the observed number of secondary colonies. This allows the data to be fitted to a logarithmic curve very precisely. Finally, the area-under-the-curve (AUC) is calculated using the trapezium rule. This step is performed because the distribution of secondary colonies per primary colony is highly skewed so that median, not mean, values are appropriate. However, in cases where fewer than 50% of the primary colonies yield secondary colonies the median will be zero and not provide any information. The AUC takes account of the proportion of CFU-GM that do not produce any secondary colonies on replating.
Fluorescence in situ hybridisation (FISH):
FISH was used to determine the Ph chromosome status of the secondary colonies derived from the cells of CML patients. All secondary colonies from each individual well were plucked into 3:1 methanol:acetic acid, transferred to multicompartmentalised slides and dried by evaporation. The slides were dehydrated in ascending concentrations of alcohol, denatured and dehydrated again. The cells were then probed using a mixture of BCR sequences labelled with SpectrumGreen and ABL sequences labelled with SpectrumOrange (Vysis, Woodcreek, IL, USA). The probe mixture was denatured at 73°C for 5 min and immediately placed on the slides on a slide warmer at 45-50°C. The slides were sealed with coverslips and incubated for 12 h at 37°C in a humidified atmosphere. Coverslips were then removed and the slides were washed in 2 × SSC, three times in 50% formamide/2 × SSC, pH 7.0-7.2, once in PBS, stained
Figure 2
The effects of IFN-␣, Ara-C or IFN-␣ + Ara-C on the selfreplication of normal (NBM) and CML CFU-GM. Colonies were grown in the presence or absence of 100 U/ml IFN-␣, 0.5 ng/ml Ara-C or both, then replated as described in Methods. Results are the means ± s.e.m. of six (NBM) or eight (CML) experiments, respectively. Statistical analysis was performed by Wilcoxon's signed rank test.
with DAPI and mounted using Vectashield (Vector Laboratories, Burlingame, CA, USA). BCR-ABL-positive cells were identified by the coincidence of green and orange signals.
Delta (⌬) assays
Delta assays for the production of CFU-GM by plastic-adherent progenitors in the CML samples were set up in the presence of combinations of IFN-␣, Ara-C and ATRA. In brief, 10 7 MNC in alpha medium plus 15% foetal calf serum were placed in tissue culture flasks. After 2 h incubation at 37°C in humidified 5% CO 2 in air, the supernatant was removed and non-adherent cells removed by three vigorous washes. The third wash was retained and assayed for CFU-GM to ensure that all of them had been washed away. Then, alpha medium containing 15% foetal calf serum, cytokines as for the CFU-GM assay (above) and 2 × 10 −6 m methylprednisolone (Upjohn, Crawley, UK). The flasks were incubated for 1 week at 37°C in humidified 5% CO 2 in air. Then, the supernatant containing non-adherent cells produced during incubation were harvested and spun down. The non-adherent cells were assayed for CFU-GM. 21 
Statistical analysis
Statistical analysis was performed using StatView SE+ graphics software for the Macintosh computer (Abacus Concepts, Berkeley, CA, USA). Paired data were compared using the Wilcoxon rank sum test.
Results
Effects of Ara-C and Ara-C + IFN-␣ on normal and CML CFU-GM Primary CFU-GM survival:
CFU-GM from NBM and CML blood were grown in the presence of 0, 0.5, 5, 50 and 500 ng/ml Ara-C (Figure 1) . CML CFU-GM were more sensitive to Ara-C with significantly reduced survival at or above 5 ng/ml (P = 0.004, n = 11) compared with NBM (n = 6) which showed a significant reduction in yield only at 500 ng/ml (3.1 ± 0.1 of controls, P = 0.0001, data not shown).
Then CFU-GM were grown in the presence of 0.5 ng/ml Ara-C ± 100 U/ml IFN-␣. As we have reported before, 11 100 U/ml IFN-␣ did not significantly alter NBM CFU-GM survival Table 1 Fluorescence in situ hybridisation analysis of secondary CFU-GM grown from primary CML CFU-GM colonies in the presence of combinations of IFN-␣ and Ara-C
Conditions
Relative (surviving fraction = 110 ± 10% of controls; mean ± s.e.m.; n = 7; P = 0.06) or CML CFU-GM (surviving fraction = 90 ± 5% of controls; n = 11; P = 0.37). There was no significant change in survival for either CML CFU-GM or NBM CFU-GM in the presence of Ara-C + IFN-␣ compared to their respective controls in the presence of Ara-C alone (data not shown).
These results indicate that CML CFU-GM may be marginally more sensitive to Ara-C than normal CFU-GM and that survival is not affected by the additional presence of a physiologically and pharmacologically relevant concentration of IFN-␣.
CFU-GM self-replication:
The effect of Ara-C on the results of replating CFU-GM, expressed as the AUC, was determined at a concentration which did not reduce the plating efficiency of primary CFU-GM, ie 0.5 ng/ml. At this concentration, neither the AUC of NBM nor that of CML CFU-GM was significantly reduced (Figure 2 ). In confirmation of previously reported results, 11 the AUC of NBM CFU-GM was not altered by growing the colonies in the presence of 100 U/ml IFN-␣ (100 ± 8.2% of controls; P = 0.9) whilst the AUC of CML CFU-GM was significantly reduced (60 ± 7% of controls; P = 0.03). When CFU-GM were grown in the presence of 0.5 ng/ml Ara-C + 100 U/ml IFN-␣, there was a significant reduction in the NBM AUC to 50 ± 10% of control values (P = 0.03) whereas for CML CFU-GM the addition of Ara-C to IFN-␣ did not further reduce the AUC. Therefore, Ara-C interacted with IFN-␣ to reduce CFU-GM self-replication in NBM cell cultures, but not in CML cell cultures. As a consequence, there was a greater suppression of the normal AUC than of the CML AUC by Ara-C + IFN-␣.
To investigate whether any of the changes in the CML cell cultures could be attributed to the activity of residual normal colony-forming cells in the patients' blood samples, we performed BCR-ABL FISH analysis of secondary colonies in four experiments. The results (Table 1) show that no Ph-negative cells could be found in any of the conditions tested. The AUC values relative to controls in this subset of experiments did not differ from the group as a whole.
Effects of ATRA and ATRA + IFN-␣ on normal and CML CFU-GM
Next we used the same approach to investigate the effects of ATRA ± IFN-␣ on normal and CML CFU-GM.
Primary CFU-GM survival:
CFU-GM from NBM and CML blood were grown in the presence of 0, 0.015, 0.15, 1.5, 15 and 150 ng/ml ATRA. Low doses (0.015-1.5 ng/ml) of ATRA
Figure 3
The effects of ATRA on the plating efficiency of normal (NBM) or CML CFU-GM. The dose-response experiments were performed to determine the highest concentration of ATRA (ie 1.5 ng/ml) which was not significantly toxic to either NBM or CML CFU-GM. Results are the means ± s.e.m. of eight (NBM) or nine (CML) experiments, respectively. Normal bone marrow controls yielded 499 ± 93 CFU-GM/10 5 mononuclear cells and CML controls yielded 785 ± 283. Statistical analysis was performed by Wilcoxon's signed rank test.
Figure 4
Effect of ATRA or IFN-␣ + ATRA on the self-replication of normal (NBM) and CML CFU-GM. Colonies were grown in the presence or absence of 1.5 ng/ml ATRA or ATRA + 100 U/ml IFN-␣, then replated as described in Methods. Results are the means ± s.e.m. of seven experiments in each group. Statistical analysis was performed by Wilcoxon's signed rank test.
significantly increased NBM plating efficiency to a maximum of nearly two-fold at 1.5 ng/ml (Figure 3 ; n = 8, P = 0.01). CML CFU-GM plating efficiency was not significantly altered by up to 15 ng/ml ATRA (n = 11). When CFU-GM were grown in the presence of 1.5 ng/ml ATRA ± 100 U/ml IFN-␣, there was no significant alteration in the primary plating efficiencies of NBM or CML CFU-GM from that observed in the presence of 1.5 ng/ml ATRA alone (data not shown).
CFU-GM self-replication:
The effect of ATRA on secondary colony formation (AUC) was determined at the concentration which maximally stimulated primary NBM CFU-GM and had no effect on CML CFU-GM survival (ie 1.5 ng/ml). ATRA significantly reduced the AUC of both NBM and CML CFU-GM to the same extent (Figure 4 ; P = 0.02 and 0.04, Leukemia respectively). When CFU-GM were grown in the presence of 1.5 ng/ml ATRA + 100 U/ml IFN-␣ there was a further significant reduction in the AUC derived from NBM CFU-GM (P = 0.03). The addition of IFN-␣ to ATRA did not further reduce the AUC of CML CFU-GM (P = 0.2). As a result, there was no difference in the reduction in the AUC for normal and CML CFU-GM grown in the presence of ATRA + IFN-␣.
Effects of Ara-C/ATRA ± IFN-␣ in delta (⌬) cultures of CML cells
Delta cultures of cells from four CML patients were set up with no addition (control) or in the presence of 100 U/ml IFN-␣, 0.5 ng/ml Ara-C, 1.5 ng/ml ATRA, Ara-C + IFN-␣ or ATRA + IFN-␣. Control cultures generated an average of 2357 CFU-GM per flask. As we have reported before, 11 addition of IFN-␣ had no significant effect on CFU-GM output compared with control values (P = 0.5). Neither were responses to Ara-C (P = 0.28), ATRA (P = 0.66), Ara-C + IFN-␣ (P = 0.83) or ATRA + IFN-␣ (P = 0.82) significantly different.
Discussion
In vitro studies of the therapeutic activity of IFN-␣ have shown that it does not act by selective toxicity against CML cells.
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Rather, it may selectively modulate the kinetics of CML haemopoietic progenitor cells so that proliferation is reduced in favour of differentiation. 11 These experiments identified expansion of the CFU-GM compartment, the most rapidly expanding compartment in CML myelopoiesis 2,13,14 as a target for IFN-␣ therapy in vivo and in vitro. The introduction of combination chemotherapy with IFN-␣ plus Ara-C in the clinic, and the suggestion that ATRA might also be used with IFN-␣, prompted this study.
There is no substantial difference between the sensitivities of normal and CML clonogenic progenitor cells to IFN-␣ in vitro. [8] [9] [10] [11] However, we found that CML CFU-GM were more sensitive to Ara-C than were normal CFU-GM in the primary colony assay. This finding agrees with the results of Sokal et al 15, 16 and suggests that Ara-C might provide therapeutic benefit as a result of preferential cytotoxicity against CML progenitor cells. In contrast, ATRA had no effect on primary colony formation by CML cells but increased the plating efficiency of normal CFU-GM two-fold. A similar increase in normal CFU-GM colony numbers has been demonstrated by Zheng et al. 19 Thus, ATRA may confer a beneficial effect in CML by stimulating normal haemopoiesis at the expense of CML cells. In our hands, the addition of IFN-␣ to Ara-C or ATRA did not change the colony-forming efficiencies of normal or CML CFU-GM compared to those observed in the presence of Ara-C or ATRA alone.
There is evidence that IFN-␣ selectively reduces the ability of CML CFU-GM to self-replicate, as revealed by the CFU-GM replating assay, but does not affect replating by normal CFU-GM. 11 Furthermore, the replating ability (AUC) of patients being treated with IFN-␣ is significantly lower than the AUC for untreated or hydroxyurea-treated CML patients. 11 The specific inhibition of Ph-positive CFU-GM self-replication in vivo is consistent with the observed haematological remission (reduced progenitor cell compartment) and gradual cytogenetic response. Antiproliferative effects of IFN-␣ are also indicated by the results of Cornelissen and colleagues. 22 These workers showed that IFN-␣ did not reduce the fre-quency of cobblestone-area-forming cells (CAFC) in CML blood and marrow, but did reduce the production of CFU-GM in long-term cultures.
Ara-C alone did not suppress the AUC of normal or CML CFU-GM, whilst ATRA reduced the AUC of normal and CML CFU-GM to the same extent. Thus, for different reasons, neither Ara-C nor ATRA induced the differential effect on normal and CML CFU-GM that was seen using IFN-␣. When used in combination with IFN-␣, both Ara-C and ATRA abolished the differential effect seen with IFN-␣ alone. That this effect was attributable to the leukaemic cells rather than a residual normal cell contribution is demonstrated by the FISH studies wherein all secondary colonies were found to be Ph-positive.
No suppressive activity of the combinations was found in the delta assay which may be considered to be an assay for more primitive cells. 20 The reasons for this lack of effect are not clear, but it is in accord with the perception that IFN-␣ may act on more mature rather than on early haemopoietic progenitor cells in CML. 9 Also, it is noteworthy that the effects reported by Cornelissen et al 22 in CAFC and long-term cultures were observed at much higher concentrations of IFN-␣ (500 and 5000 units per ml) than we have used here.
Our results are not inconsistent with the reported efficacy of combined therapy with IFN-␣ and Ara-C 17 since both agents have separate therapeutic effects on CFU-GM. However, they may not support the contemporaneous administration of IFN-␣ and Ara-C/ATRA. The abrogation of the action of IFN-␣ during periods when both agents are present could lead to extra toxicity and less therapeutic benefit. Indeed, a clinical benefit of the currently used Ara-C/IFN-␣ combination may only be achievable at the expense of high toxicity and very low leukocyte counts. 23 In summary, the selective effects of IFN-␣, Ara-C and ATRA on CML progenitor cells are mediated by preferential suppression of progenitor cell proliferation, selective cytotoxicity towards CML progenitor cells and selective stimulation of normal colony formation, respectively. All of these different activities are capable of conferring therapeutic benefit. However, the selective effects of IFN-␣ on CML progenitor cell kinetics are reduced or even abrogated in the presence of Ara-C or ATRA. Consequently, modifying combined treatment regimens to alternating rather than combined administration may offer better prospects for further improvements in the outcome of CML therapy.
